Regulation of AKT signaling by Id1 controls t(8;21) leukemia initiation and progression

Lan Wang, Na Man, Xiao Jian Sun, Yurong Tan, Marta Garcia Cao, Fan Liu, Megan Hatlen, Haiming Xu, Gang Huang, Meredith Mattlin, Arpit Mehta, Evadnie Rampersaud, Robert Benezra, Stephen D. Nimer

Research output: Contribution to journalArticlepeer-review

28 Scopus citations

Abstract

Transcriptional regulators are recurrently altered through translocations, deletions, or aberrant expression in acute myeloid leukemia (AML). Although critically important in leukemogenesis, the underlying pathogenetic mechanisms they trigger remain largely unknown. Here, we identified that Id1 (inhibitor of DNA binding 1) plays a pivotal role in acute myeloid leukemogenesis. Using genetically modified mice, we found that loss of Id1 inhibited t(8;21) leukemia initiation and progression in vivo by abrogating protein kinase B (AKT)1 activation, and that Id1 interacted with AKT1 through its C terminus. An Id1 inhibitor impaired the in vitro growth of AML cells and, when combined with an AKT inhibitor, triggered even greater apoptosis and growth inhibition, whereas normal hematopoietic stem/progenitor cells were largely spared. We then performed in vivo experiments and found that the Id1 inhibitor significantly prolonged the survival of t(8;21)1 leukemic mice, whereas overexpression of activated AKT1 promoted leukemogenesis. Thus, our results establish Id1/Akt1 signaling as a potential therapeutic target in t(8;21) leukemia.

Original languageEnglish (US)
Pages (from-to)640-650
Number of pages11
JournalBlood
Volume126
Issue number5
DOIs
StatePublished - Jul 30 2015
Externally publishedYes

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Fingerprint

Dive into the research topics of 'Regulation of AKT signaling by Id1 controls t(8;21) leukemia initiation and progression'. Together they form a unique fingerprint.

Cite this